(photo courtesy hivresearch.org)

Rare Encouraging News in HIV and Parkinson’s Disease

HIV/AIDS and Parkinson’s Disease are two areas of medical research where good news is hard to come by, as researchers encounter countless setbacks in trying to translate promising laboratory findings into clinical practice. Both diseases have seen progress in the past decade in ex post facto treatments - preventing the maturity of HIV into AIDS with antiretroviral treatment or reducing the motor symptoms associated with Parkinson’s. But drugs that seemed to offer a cure for either disease, or in the case of Parkinson’s a mere brake to the progression of symptoms, have consistently disappointed in human trials.

That changed - slightly - this week, as two highly-publicized studies were published offering faint glimmers of hope on both disease fronts. Grabbing the most headlines was the first-ever demonstration of a successful HIV vaccine in a study conducted in Thailand but funded by the U.S. Army and the National Institutes of Health. The caveats are flying hot and heavy - the researchers saw only a 31% decrease in the number of HIV cases after treatment with a vaccine and a booster drug, one of the HIV strains protected against is specific to southeast Asia, and mystery lingers over why this particular combination of drugs was protective where so many others have failed. The two drugs used in the Thai trial - one a “primer” and one a “booster” - had themselves failed in previous large clinical trials. But the first small success in protecting against the deadly virus nevertheless encouraged many HIV/AIDS researchers; Dan Barouch, an immunologist at the Beth Israel Deaconess Medical Center in Boston, Massachusetts, told Nature “It’s the largest step forward that’s ever occurred in the HIV-vaccine field, but there’s a tremendous amount of more work that will need to be done.”

read more

The death of Michael Jackson has made its expected transition from a celebration of his life and music to an uncomfortable public autopsy of how he died. More than a month after his death, the official coroner’s autopsy has yet to be officially released, but various media outlets have sniffed out one particular drug that is expected to appear in the pop star’s toxicology report: the general anesthetic propofol.

The widely-used but little-discussed drug has provoked a number of “what is Propofol?” news segments, including a piece by ABC’s Primetime: Crime that brought a camera crew to the University of Chicago Medical Center earlier this week. That segment, reported by former MTV newsman Chris Connelly aired Wednesday night, and you can watch it here.

For 30 seconds (from -2:17 to -1:47) of the video, you’ll hear briefly about research by Avery Tung, associate professor of anesthesia and critical care for the Medical Center (you will also see a rat being anesthetized with a completely different drug, halothane). In the early part of the decade, Tung conducted an NIH-funded research project examining relationships between sleep and anesthesia, and published several papers and scientific abstracts looking at how propofol mimicked the effects of actual sleep. After Tung sat down with ABC, I spent a little more time with him discussing the anesthetic and his research.

Q: First of all, what is propofol, and how often is it used?

Tung: Propofol is given intravenously to induce anesthesia in surgical patients and to provide sedation for patients in the Intensive Care Unit. It’s the most common induction agent of anesthesia in current use. It pretty much has replaced pentothal because it has fewer side effects and it makes people feel better when they wake up.

read more